Bayer has selected six startups from 310 applicants for the 2026 edition of its G4A Accelerator Program in Türkiye. The participants will receive a 100-day acceleration program, mentorship, business development support, and opportunities to collaborate with Bayer.
Bayer has announced the six startups selected for the 2026 G4A Accelerator Program, an initiative run in partnership with Tenity to support innovation in pharmaceuticals, consumer health, and crop science. The startups will participate in a 100-day acceleration program, while three of them will also receive TL 500,000 in grant funding.
Bayer has announced the six startups selected for the 2026 G4A Accelerator Program in Türkiye, choosing them from 310 applications submitted across its Pharmaceuticals, Consumer Health, and Crop Science business divisions.
The program, organized in partnership with Tenity, has supported Türkiye’s startup ecosystem since 2018 by connecting early-stage companies with industry experts, mentors, and business development opportunities.
The selected startups are Pearly Menopoz Platformu, RaporinAI, Vinter (Vindy), NeoOne Teknoloji, Tekno Kurgu, and MOVE ON.
100-day acceleration program
The selected companies will participate in a 100-day acceleration program that includes mentoring, technical guidance, product development support, networking opportunities, access to software services, and potential collaboration with Bayer’s business units.
The program is designed to help startups refine their technologies, validate business models, and prepare for commercial growth.
Grant funding for three startups
Among the six selected companies, Pearly Menopoz Platformu, Vinter (Vindy), and Tekno Kurgu were also awarded TL 500,000 each in grant funding.
According to Bayer, the financial support is intended to help accelerate product development and facilitate the commercialization of innovative solutions.
Supporting innovation in health and agriculture
The G4A Accelerator Program focuses on startups developing digital solutions in healthcare, consumer health, and agricultural technologies. In addition to mentoring and training, participants gain access to Bayer’s global network and opportunities to collaborate with corporate experts and industry stakeholders.
Since its launch in Türkiye in 2018, the initiative has aimed to strengthen the country’s innovation ecosystem by supporting scalable technologies capable of addressing healthcare and agricultural challenges.
Why It Matters
The G4A Accelerator Program reflects growing collaboration between global life sciences companies and technology startups to accelerate innovation. By combining mentorship, financial support, and access to industry expertise, accelerator programs can help early-stage companies bring new healthcare and agricultural technologies to market more rapidly.
Frequently Asked Questions
What is the Bayer G4A Accelerator Program?
The G4A Accelerator Program is Bayer’s startup support initiative, developed in partnership with Tenity, to help innovative companies in pharmaceuticals, consumer health, and agricultural technologies scale their businesses.
How many startups were selected in 2026?
Six startups were selected from a pool of 310 applications for the 2026 program.
Which startups received grant funding?
Pearly Menopoz Platformu, Vinter (Vindy), and Tekno Kurgu each received TL 500,000 in grant funding in addition to joining the accelerator program.
What support do participating startups receive?
Participants receive a 100-day acceleration program that includes mentorship, business development, networking opportunities, technical support, software services, and potential collaboration with Bayer.
Source: Bayer Türkiye, G4A Türkiye
This content has been prepared solely for news and general information purposes. The information provided herein is not intended for diagnosis or treatment. Please consult your doctor or a qualified healthcare provider regarding decisions concerning your health. Our website is not liable for any direct or indirect consequences arising from the use of the published information.
